A randomized double blind placebo controlled study on the effects of fenretinide Lym-X-Sorb on insulin sensitivity in obese insulin resistant subjects

Trial Profile

A randomized double blind placebo controlled study on the effects of fenretinide Lym-X-Sorb on insulin sensitivity in obese insulin resistant subjects

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Nov 2017

At a glance

  • Drugs Fenretinide (Primary)
  • Indications Insulin resistance
  • Focus Biomarker; Pharmacodynamics
  • Acronyms FEN
  • Most Recent Events

    • 16 Jul 2012 New trial record
    • 15 Jul 2012 Planned end date 1 Apr 2014 added as reported by Netherlands Trial Register record.
    • 15 Jul 2012 New source identified and integrated (Netherlands Trial Register, NTR3502).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top